Journal ArticleDOI
Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients: Clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia
Anne C. Goldberg,Paul N. Hopkins,Peter P. Toth,Christie M. Ballantyne,Daniel J. Rader,Jennifer G. Robinson,Stephen R. Daniels,Samuel S. Gidding,Sarah D. de Ferranti,Matthew K. Ito,Mary P. McGowan,Patrick M. Moriarty,William C. Cromwell,Joyce L. Ross,Paul Ziajka +14 more
Reads0
Chats0
TLDR
This report goes beyond previously published guidelines by providing specific clinical guidance for the primary care clinician and lipid specialist with the goal of improving care of patients with FH and reducing their elevated risk for CHD.About:
This article is published in Journal of Clinical Lipidology.The article was published on 2011-05-01. It has received 560 citations till now. The article focuses on the topics: Familial hypercholesterolemia & Lomitapide.read more
Citations
More filters
Journal ArticleDOI
Combination therapy in dyslipidemia: Where are we now?
Alberico L. Catapano,Michel Farnier,JoAnne M. Foody,Peter P. Toth,Joanne E. Tomassini,Philippe Brudi,Andrew M. Tershakovec +6 more
TL;DR: A review of the evidence for statin use in combination with fibrates, niacin, bile acid sequestrants, and the cholesterol absorption inhibitor, ezetimibe, in dyslipidemic patients at increased risk of cardiovascular disease explores the impact of such combination therapies on lipids, attainment of lipid targets, inflammatory markers, and on cardiovascular outcomes and pathology.
Journal ArticleDOI
Review of clinical practice guidelines for the management of LDL-related risk.
TL;DR: The similarities and differences among important guidelines in the United States and internationally are discussed, with recommendations for future strategies to improve consistency in approaches to LDL-related ASCVD risk and to reduce gaps in implementation of evidence-based therapies.
Journal ArticleDOI
Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia.
Kiyohito Arai,Alexina Orsoni,Ziad Mallat,Ziad Mallat,Alain Tedgui,Joseph L. Witztum,Eric Bruckert,Alexandros D. Tselepis,M. John Chapman,Sotirios Tsimikas +9 more
TL;DR: The impact of apheresis on Lp(a), OxPL, and Lp-PLA2 provides insights into its therapeutic benefits beyond lowering apoB-containing lipoproteins.
Journal ArticleDOI
Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia.
Sofía Pérez-Calahorra,Martín Laclaustra,Victoria Marco-Benedí,Itziar Lamiquiz-Moneo,Juan Pedro-Botet,Núria Plana,Rosa M. Sánchez-Hernández,Antonio J. Amor,Fátima Almagro,Francisco Fuentes,Manuel Suárez-Tembra,Fernando Civeira +11 more
TL;DR: Current prevalence of CVD among HeFH is one third of that reported before the statins era, and early initiation and prolonged lipid-lowering treatment was associated with a reduction in CVD.
Journal ArticleDOI
Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
TL;DR: The inhibition of PCSK9 in combination with statins provides a promising approach for lowering low-density lipoprotein cholesterol (LDL-C) concentrations.
References
More filters
Journal ArticleDOI
Hyperlipidemia in Coronary Heart Disease II. GENETIC ANALYSIS OF LIPID LEVELS IN 176 FAMILIES AND DELINEATION OF A NEW INHERITED DISORDER, COMBINED HYPERLIPIDEMIA
TL;DR: The combined disorder was shown to be genetically distinct from familial hypercholesterolemia and familial hypertriglyceridemia for the following reasons: the distribution pattern of cholesterol and triglyceride levels in relatives of probands was unique.
Journal ArticleDOI
Lipid Screening and Cardiovascular Health in Childhood
TL;DR: The need for prevention of cardiovascular disease by following Dietary Guidelines for Americans and increasing physical activity is reemphasized and the need for pharmacologic agents and indications for treating dyslipidemia in children are reviewed.
Journal ArticleDOI
Efficacy of statins in familial hypercholesterolaemia: a long term cohort study
Jorie Versmissen,Daniëlla M. Oosterveer,Mojgan Yazdanpanah,Joep C. Defesche,Dick C. Basart,Anho H Liem,Jan Heeringa,Jacqueline C.M. Witteman,P. J. Lansberg,John J.P. Kastelein,Eric J.G. Sijbrands +10 more
TL;DR: Lower statin doses than those currently advised reduced the risk of coronary heart disease to a greater extent than anticipated in patients with familial hypercholesterolaemia.
Journal ArticleDOI
Genetic Causes of Monogenic Heterozygous Familial Hypercholesterolemia: A HuGE Prevalence Review
TL;DR: The clinical phenotype of heterozygous familial hypercholesterolemia (FH) is characterized by increased plasma levels of total cholesterol and low density lipoprotein cholesterol, tendinous xanthomata, and premature symptoms of coronary heart disease.
Journal ArticleDOI
Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia.
TL;DR: These guidelines have been elaborated by a group of international experts with the intention to answer the main questions about heterozygous FH (heFH) subjects that physicians worldwide face in the diagnosis and management of these patients.
Related Papers (5)
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society
Børge G. Nordestgaard,M. John Chapman,Steve E. Humphries,Henry N. Ginsberg,Luis Masana,Olivier S. Descamps,Olov Wiklund,Robert A. Hegele,Frederick J. Raal,Joep C. Defesche,Albert Wiegman,Raul D. Santos,Gerald F. Watts,Klaus G. Parhofer,G. Kees Hovingh,Petri T. Kovanen,Catherine Boileau,Maurizio Averna,Jan Borén,Eric Bruckert,Alberico L. Catapano,Jan Albert Kuivenhoven,Jan Albert Kuivenhoven,P. Pajukanta,Kausik K. Ray,Anton F. H. Stalenhoef,Erik S.G. Stroes,Marja-Riitta Taskinen,Anne Tybjærg-Hansen +28 more
Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society
Marina Cuchel,Eric Bruckert,Henry N. Ginsberg,Frederick J. Raal,Raul D. Santos,Robert A. Hegele,Jan Albert Kuivenhoven,Børge G. Nordestgaard,Olivier S. Descamps,Elisabeth Steinhagen-Thiessen,Anne Tybjærg-Hansen,Gerald F. Watts,Maurizio Averna,Catherine Boileau,Jan Borén,A.L. Catapano,Joep C. Defesche,G. Kees Hovingh,Steve E. Humphries,Petri T. Kovanen,Luis Masana,Päivi Pajukanta,Klaus G. Parhofer,Kausik K. Ray,Anton F. H. Stalenhoef,Erik S.G. Stroes,Marja-Riitta Taskinen,Albert Wiegman,Olov Wiklund,M. John Chapman +29 more
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)☆☆☆
Alberico L. Catapano,Zeljko Reiner,Guy De Backer,Ian D. Graham,Marja-Riitta Taskinen,Olov Wiklund,Stefan Agewall,Eduardo Alegria,M. John Chapman,Paul N. Durrington,Serap Erdine,Julian Halcox,Richard J. Hobbs,John Kjekshus,Pasquale Perrone Filardi,Gabriele Riccardi,Robert F. Storey,David R. Wood +17 more